• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    8/23/24 5:33:46 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email
    SC 13D/A 1 opk20240821c_sc13da.htm SCHEDULE 13D/A opk20240821c_sc13da.htm

     



     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 6*)

     

    GeneDx Holdings, Corp.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    81663L200

    (CUSIP Number)

     

    Steven D. Rubin

    Executive Vice President - Administration

    OPKO Health, Inc.

    4400 Biscayne Boulevard

    Miami, Florida 33137

    Telephone: (305) 575-4100

     

    (Name, address and telephone number of person authorized to receive notices and communications)

     

     

    August 22, 2024

    (Date of event which requires filing of this statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     



     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 2 of 5

     

     

    1

     

    NAME OF REPORTING PERSONS

     

    OPKO Health, Inc.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☐        (b)  ☐

    3

     

    SEC USE ONLY

     

    4

     

    SOURCE OF FUNDS

     

    OO

    5

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☒

     

    6

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    7

     

    SOLE VOTING POWER

     

    NUMBER OF     2,502,146

    Shares

    SHARES

    BENEFICIALLY

    8

     

    SHARED VOTING POWER

     

    OWNED BY

        -  

    EACH REPORTING

    PERSON

    9

     

    SOLE DISPOSITIVE POWER

     

    WITH     2,502,146  
     

    10

     

    SHARED DISPOSITIVE POWER

     

          -  

    11

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        2,502,146  

    12

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

    13

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

       

    9.29%(1)

    14

     

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)

    Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on July 30, 2024.

     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 3 of 5

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 6 (the “Amendment”) to Schedule 13D is being filed with the Securities and Exchange Commission (the “SEC”) on behalf of OPKO Health, Inc., a Delaware corporation (“OPKO”) and relates to the Class A common stock, par value $0.0001 per share (“GeneDx Common Stock”), of GeneDx Holdings Corp., a Delaware corporation (“GeneDx” or the “Issuer”) and amends and supplements the initial statement on Schedule 13D filed by OPKO with the SEC on May 9, 2022, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on February 3, 2023, as amended by Amendment No. 2 filed with the SEC on April 20, 2023, as amended by Amendment No. 3 filed with the SEC on July 5, 2024, as amended by Amendment No. 4 filed with the SEC on July 26, 2024, as amended by Amendment No. 5 filed with the SEC on August 12, 2024  (the “Schedule 13D”).  Capitalized terms used but not defined in this Amendment No. 6 shall have the same meanings ascribed to them in the Schedule 13D. 

     

    ITEM 4.

    Purpose of Transaction.

     

    Item 4 is amended by adding the following paragraph to the end of the item:

     

    In a series of transactions between August 13, 2024 and August 23, 2024, OPKO sold a total of 309,637 shares of GeneDx Common Stock on the open market at prices ranging from $33.00 to $35.9175 per share for an aggregate sale price of approximately $10,632,473.

     

    ITEM 5.

    Interest in Securities of the Issuer.

     

    Item 5 is deleted in its entirety and replaced with the following text:

     

    (a)          The Company’s beneficial ownership of GeneDx Common Stock is as set forth in the table below:

     

    Name and Title of Beneficial Owner

     

    Number of Outstanding Shares Beneficially Owned

     

    Percentage of Outstanding Common Shares (1)

    OPKO Health, Inc.

     

    2,502,146

     

    9.29%

    ______________

    (1)  Based on 26,935,897 shares of GeneDx Common Stock of the Issuer outstanding on July 22, 2024, as set forth in the Issuer’s Form 10-Q filed with the SEC on July 30, 2024.

     

    (b)          Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5.

     

    (c)          In the last 60 days prior to the filing of this Amendment No. 6, OPKO sold a total of 1,056,457 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $35.9175 per share for an aggregate sale price of approximately $34,703,115. Sales of GeneDx Common Stock prior to August 13, 2024 were previously reported in Amendment No. 4 and Amendment No. 5. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days.

     

    Date

     

    Shares of Common Stock

     

    Aggregate Purchase Price

     

    Weighted Price Per

    Share

    7/1/24   50,000  

    $

    1,331,669  

    $

    26.6340
    7/2/24   25,000  

    $

    728,095  

    $

    29.1238
    7/3/24   14,082   $ 397,491   $ 28.2269
    7/5/24   36,118   $ 1,020,015   $ 28.2412
    7/17/24   25,000   $ 823,187   $ 32.9275
    7/19/24   25,000   $ 807,250   $ 32.29
    7/22/24   50,000   $ 1,630,422   $

    32.6088

    7/23/24   75,000   $ 2,509,248   $ 33.4566
    7/24/24   75,000   $ 2,529,102   $ 33.7214
    7/26/24   60,000   $ 2,031,255   $ 33.8543
     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 4 of 5

     

    7/29/24   50,000   $ 1,692,890   $ 33.8578
    7/31/24   88,839   $ 2,976,350   $ 33.5027
    8/6/24   12,994   $ 381,427   $ 29.3541
    8/8/24   100,000   $ 3.182.380   $ 31.8238
    8/12/24   59,787   $ 2,029,811   $ 33.9507

    8/13/24

      24,987   $ 868,502   $ 34.7582
    8/15/24   39,824   $ 1,317,506   $ 33.0832
    8/16/24   50,000   $ 1,714,851   $ 34.2970
    8/19/24   50,000   $ 1,724,519   $ 34.4904
    8/21/24   94,826   $ 3,270,681   $ 34.4914
    8/22/24   25,000   $ 851,946   $ 34.0779
    8/23/24   25,000   $ 884,466   $ 35.3786

     

    (d)          Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.

     

    (e)          Not applicable.

     

     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 5 of 5

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

              OPKO Health, Inc.
             

    Dated:

    August 23, 2024      

    By:

      /s/ Steven D. Rubin
             

    Name:

      Steven D. Rubin
             

    Title:

     

    Executive Vice President - Administration

                   

     

     
    Get the next $WGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Meister Keith A. was granted 434,848 shares (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/6/25 9:45:05 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Director Pfenniger Richard C Jr converted options into 918 shares, increasing direct ownership by 3% to 28,582 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/5/25 4:48:43 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 753 shares, sold $43,879 worth of shares (388 units at $113.09) and was granted 420 shares, increasing direct ownership by 26% to 3,757 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/1/25 7:46:17 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by GeneDx Holdings Corp.

      DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:34:16 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form DEF 14A filed by GeneDx Holdings Corp.

      DEF 14A - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 4:33:10 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by GeneDx Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      4/30/25 7:04:19 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on GeneDx with a new price target

      Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00

      8/28/24 7:58:09 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Craig Hallum initiated coverage on GeneDx with a new price target

      Craig Hallum initiated coverage of GeneDx with a rating of Buy and set a new price target of $43.00

      7/10/24 8:09:23 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Jefferies resumed coverage on GeneDx with a new price target

      Jefferies resumed coverage of GeneDx with a rating of Hold and set a new price target of $21.00

      6/3/24 8:54:48 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GeneDx Announces Completion of Fabric Genomics Acquisition

      Closing unlocks the next phase of genomic medicine, enabling an end-to-end centralized and decentralized model for offering clinically-actionable genomic insights at a global scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the successful completion of its acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. Together, GeneDx and Fabric Genomics are ushering in the next era of genomic medicine, enabling decentralized testing powered by centralized intelligence to set the standard of care across the globe. "Healthcare is at an inflection point where genomic insights must be integrated into standar

      5/7/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

      Combining GeneDx's industry-leading rare disease data asset and Fabric Genomics' AI-powered platform furthers the Company's leadership and creates an unrivaled platform to deliver global access to genomic information Accelerates the NICU, enables newborn screening, and opens global market opportunities with on-site sequencing and decentralized interpretation GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced its plans to acquire Fabric Genomics, a pioneer in AI-powered genomic interpretation. The transaction enables GeneDx's leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence. "H

      4/16/25 6:00:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $WGS
    Leadership Updates

    Live Leadership Updates

    See more

    $WGS
    Financials

    Live finance-specific insights

    See more

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/20/24 9:36:13 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/19/24 8:00:24 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/8/24 5:23:34 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

      Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

      1/2/25 4:01:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

      Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

      11/18/24 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      4/8/25 8:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment
    • Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      6/5/24 8:45:06 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $842,604 worth of shares (40,000 units at $21.07) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/31/24 5:37:30 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $3,424,989 worth of shares (170,000 units at $20.15) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/28/24 8:40:42 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology